Could popular Weight-Loss drugs harm your teeth? a new study investigates

NCT ID NCT07720466

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study looks at whether GLP-1 receptor agonists like semaglutide and tirzepatide, used for weight loss, change saliva composition and increase tooth wear. Researchers will measure saliva calcium, pH, flow rate, and dental erosion in 40 adults before and 3 months after starting the medication. The goal is to understand potential oral health side effects and help clinicians prevent dental complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide or tirzepatide (GLP-1 receptor agonists)
What this could lead to
If it finds clear links, this could help doctors monitor and prevent dental problems in people taking GLP-1 drugs for obesity.
What could go wrong
This is a small, early observational study with only 40 participants and no control group, so results may not apply broadly. It measures changes over just 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENTAL EROSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Periodontology, Bilecik Seyh Edebali University Faculty of Dentistry

    Bilecik, Merkez, 11100, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.